Bionomics to Participate in Upcoming September Investor Conferences

Rhea-AI Summary

Bionomics Limited (ASX:BNO, NASDAQ:BNOX), a clinical-stage biopharmaceutical company, has announced its participation in several investor conferences this September. Key events include Citi’s 17th Annual BioPharma Conference in Boston on September 8, H.C. Wainwright 24th Annual Global Investment Conference in New York City on September 12 at 12:30 PM ET, and the Ladenburg Thalmann Healthcare Conference 2022 in New York City on September 29 at 4:00 PM ET. Audio webcasts for select events will be available on their Investors website.

ADELAIDE, Australia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will participate in the following upcoming investor conferences in September:

• Citi’s 17th Annual BioPharma Conference
  • Taking place in-person in Boston on September 8^th  
• H.C. Wainwright 24th Annual Global Investment Conference
  • Company Presentation: September 12^th at 12:30pm ET in New York City
• Ladenburg Thalmann Healthcare Conference 2022
  • Company Presentation: September 29^th at 4:00pm ET in New York City

An audio webcast link for select events, when available, will be posted to Bionomics’ website in the Events and Presentations page of the Investors section.

Released on authority of the Executive Chairman.

FOR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations Mr. Connor Bernstein Vice President, Strategy and Corporate Development +1 (650) 524-5143 cbernstein@bionomics.com.au

Investor Relations Kevin Gardner kgardner@lifesciadvisors.com

About Bionomics Limited
Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
www.bionomics.com.au

FAQ

What investor conferences is Bionomics participating in September 2022?

Bionomics will attend Citi’s 17th Annual BioPharma Conference on September 8, H.C. Wainwright 24th Annual Global Investment Conference on September 12, and the Ladenburg Thalmann Healthcare Conference on September 29.

When is Bionomics presenting at the H.C. Wainwright conference?

Bionomics will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 12:30 PM ET.

Where can I find Bionomics' investor conference audio webcasts?

Audio webcasts for select investor conferences will be posted on Bionomics' Investors website under the Events and Presentations page.

What is the focus of Bionomics as a biopharmaceutical company?

Bionomics focuses on developing novel allosteric ion channel modulators for serious central nervous system disorders, including therapies for Social Anxiety Disorder and Post-Traumatic Stress Disorder.

What is the ticker symbol for Bionomics?

Bionomics is traded under the ticker symbols ASX:BNO and NASDAQ:BNOX.